Tacodelphia » 2016 » September

Ruminations of a Taco-Obsessed Philly Native

UPDATE — Octoer 17th, 2016 — Seattle Genetics makes good on their word to hire 100 more employees : http://www.bizjournals.com/seattle/blog/health-care-inc/2016/03/seattle-genetics-ambitious-plan-for-12-more-drugs.html


Seattle Genetics is a biotechnology company that are leaders in the study of antibody drugs to treat cancer. The company was started in 1998 in Bothell, Washington by Clay Siegall. Bothell, Washington is a suburb of Seattle. The company employs some five hundred to one thousand employees.

The technology at Seattle Genetics takes monoclonal antibodies to kill cancerous cells. Their leading study is the ADCETRIS. The ADCETRIS is the first of the ADCs tests. ADC stands for antibody drug conjugates.

Clay Siegall is the present president and the founder of Seattle Genetics. He studied at the University of Maryland to earn a Bachelor of Science, Zoology degree. He was alumnus of the year in computer, math and science at University of Maryland. Clay Siegall went on to The George Washington University to earn a Ph. D in Genetics. Pacific Northwest Ernst and Young voted him entrepreneur of the year in 2012.

Clay Siegall is additionally the director of many biotechnology companies. He is the director of Alder Biopharmaceuticals, Mirna Therapeutics and Ultragenyx Pharmaceutical.

Dr. Clay Siegall started Seattle Genetics because he has always focused on treating cancer. The purpose of Seattle Genetics is to develops ADCs to treat all types of cancers. With Dr. Clay Siegall leading the company, Seattle Genetics has made over three hundred million dollars. The company has additionally secured more licenses for their ADCs technology under Dr. Siegall’s leadership. Seattle Genetics now have licenses with Genentech, AbbVie, GlaxoSmithKline and Plitzer, which help to improve the ADCs cancer fighting technology.

Seattle Genetics is a biotechnology firm that produces and commercializes innovative antibody therapies for the treatment of cancer and related diseases. The company is an industry leader in antibody-drug conjugates, an innovation aimed at harnessing the targeting abilities of monoclonal antibodies by connecting them with cell-killing agents. The firm has three platform technologies: antibody-drug conjugates (ADCs), antibody-directed enzyme prodrug therapy (ADEPT) and engineered monoclonal antibodies.

Seattle Genetics has created an assortment of products that are targeted to several types of human cancer, two of which are currently being tested in several ongoing clinical trials. Clay Siegall’s biotechnology firm has agreements with other companies such as Genencor International, Bristol-Myers Squibb, and Medarex. The company also holds licenses for its ADC technology with Eos Biotechnology, Genentech and Celltech Group.

Seattle Genetics was established in 1997 and has its headquarters located in Bothell, Washington. Among the founders of the firm is Clay B. Siegall, a renowned scientist in the field of biotechnology. Mr. Siegall serves as the president and Chief Executive Officer and is also the chair of the board. Dr. Siegall built Seattle Genetics on the basis of scientific advancement, drug development activities, thorough research and a passion for assisting patients. Through his hard work and devotion, Dr. Siegall has successfully guided the firm to its current leadership position in creating antibody-drug conjugates (ADCs) for treating cancer.

Dr. Clay B. Siegall’s reign as the president and CEO of Seattle Genetics has seen him develop an assortment of antibody-based cancer therapies such as ADCETRIS (brentuximab vedotin) which received quick approval by the FDA in 2011. He has also been on the front line in guiding Seattle Genetics’ capital funding activities, raising more than $675 million through private and public funding.

Mr. Siegall studied Bachelor of Science (B.S.), Zoology from the University of Maryland and holds a Doctor of Philosophy (Ph.D.) in Genetics from The George Washington University. Dr. Siegall has spent almost two decades understanding the science behind cancer and producing therapeutic drugs to treat several types of the ailment. Before co-founding Seattle Genetics, Mr. Siegall worked for Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997. From 1988 to 1991, Siegall worked for the National Cancer Institute, National Institutes of Health.
Mr. Siegall was appointed as a member of the Board of Directors of the biotechnology-based company, Mirna Therapeutics in January 2013. In his capacity, he would serve as an outside director. Mirna Therapeutics (Austin, Texas) was founded in 2007 and deals with microRNA in therapeutics.

Original Articles:



Recidivism is an out-of-control problem almost as bad as increasing prison populations, and certainly doing nothing to curb overcrowding among correctional facilities. Many rehabilitative techniques do nothing to discourage criminal activity. More money is needed to discover techniques that offer return on investment. There’s no good spending ten million to curb recidivism if there’s no statistical change in crime rates. Thankfully, because of Securus Technologies, there is a potential for over $70,000,000 to be freed up nationwide on a case-by-case basis per correctional facility. The possibilities come through ConnectUs Automated Forms, which is a new innovation that consolidates time and resources into a single location; curbing their expense.


Paper costs money. Printers cost money. Pencils, pens, paper clips, staplers, file cabinets, storage, and secretaries are expensive. All of these things are outdated 20th century concepts who have no real business in the 21st century. With ConnectUs automated forms, the vast majority of these accoutrements can be entirely eliminated from the budget. To prove the $70,000,000 figure, consider the case of one area where ConnectUs Automated Forms saves facilities thousands. In the area of complaints and grievances forms, an average inmate will file 13.8 a month. Between transport, filing, and dealing with the form, much more than five minutes is spent per form. However, five minutes will be used to yield a conservative estimate. At five minutes per form, each inmate takes up 13.8 hours of staff time every year with his or her complaint articles. Multiplied across a facility of 100 inmates, that comes to 1,380 hours. At only $10 an hour, that’s $13,800. But employees cost more than that, with benefits, insurance, etc. $20/hour is more realistic; or $27,600 per 100-inmate facility annually. Securus deals with 2,600 facilities every year, so the potential savings here is $71,760,000. A chunk of change like that could do a lot to help reduce recidivism.